Kimberly-Clark

Kimberly-Clark has completed its acquisition of consumer health company Kenvue, with the merger closing on November 2, 2026. Kenvue now operates as a subsidiary under the name Kenvue LLC. Kenvue shareholders received 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share held, uniting brands from both companies under one consumer goods group.

Financial outlet 24/7 Wall St. outlines a three-fund dividend portfolio built from Kimberly-Clark, the VanEck BIZD ETF, and the SPDR SPHD ETF, arguing its income can fully cover retirees' required minimum distributions without forcing share sales. The pitch targets older investors seeking steady cash flow from holdings rather than liquidating positions to meet IRS withdrawal rules.

Kimberly-Clark Corporation completed its acquisition of Kenvue Inc. on November 2, 2026, turning the consumer health company into a subsidiary named Kenvue LLC. Under the deal terms, Kenvue shareholders received $3.50 in cash plus 0.14625 shares of Kimberly-Clark stock per share held. Market watchers are tracking the implications for the combined consumer products giant, which now spans household staples and brands like Tylenol and Neutrogena.

Kimberly-Clark (KMB) has filed an S-8 registration statement with the US Securities and Exchange Commission. S-8 filings are used to register securities offered to employees under benefit plans, such as stock option or purchase schemes. The filing is being tracked by investors following the company's regulatory disclosures on financial news platforms.